TNXP
Tonix Pharmaceuticals Holding Corp.
Price Chart
Latest Quote
$12.43
+0.58 (+4.89%)
Current Price
| Previous Close | $11.85 |
| Open | $11.64 |
| Day High | $12.76 |
| Day Low | $11.49 |
| Volume | 688,309 |
Stock Information
| Shares Outstanding | 15.94M |
| Total Debt | $1.29M |
| Cash Equivalents | $185.47M |
| Revenue | $17.56M |
| Net Income | $-147.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $198.14M |
| EPS (TTM) | $-14.66 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.96M |
| Sales | $17.56M |
| Income | $-147.39M |
| Book/sh | $15.99 |
| Cash/sh | $11.63 |
| Employees | 142 |
Financial Ratios
| Quick Ratio | 6.57 |
| Current Ratio | 6.99 |
| Debt/Eq | 0.57 |
Returns & Margins
| ROA | -41.92% |
| ROE | -72.33% |
| Gross Margin | 58.56% |
| Operating Margin | -603.91% |
Ownership
| Insider Ownership | 0.14% |
| Institutional Ownership | 45.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.59 |
| P/S | 11.29 |
| P/B | 0.78 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $42.20 |
Technical Indicators
| SMA20 | $12.31 |
| SMA50 | $12.57 |
| SMA200 | $15.45 |
| RSI | 41.99 |
| ATR | 0.8507 |
| Shares Float | 15.01M |
| Short Float | 22.50% |
| Short Ratio | 5.90 |
| Volatility | 1.65 |
| Rel Volume | 1.24 |
Performance History
| Week | -0.80% |
| Month | +6.88% |
| Quarter | -12.03% |
| 6 Months | -26.45% |
| YTD | -24.89% |
| Year | -72.41% |
| 3 Years | -99.79% |
| 5 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $12.43 | 688,309 |
| 2026-07-16 | $11.85 | 420,300 |
| 2026-07-15 | $11.61 | 362,000 |
| 2026-07-14 | $11.06 | 617,600 |
| 2026-07-13 | $11.71 | 1,029,500 |
| 2026-07-10 | $12.53 | 506,000 |
| 2026-07-09 | $13.03 | 740,800 |
| 2026-07-08 | $12.78 | 691,900 |
| 2026-07-07 | $12.71 | 262,000 |
| 2026-07-06 | $12.71 | 188,700 |
| 2026-07-02 | $12.34 | 326,400 |
| 2026-07-01 | $12.44 | 288,200 |
| 2026-06-30 | $12.76 | 308,600 |
| 2026-06-29 | $12.75 | 525,700 |
| 2026-06-26 | $13.22 | 1,608,900 |
| 2026-06-25 | $11.98 | 717,700 |
| 2026-06-24 | $12.10 | 401,200 |
| 2026-06-23 | $11.96 | 466,900 |
| 2026-06-22 | $12.20 | 396,100 |
| 2026-06-18 | $12.01 | 567,100 |
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
đ° Latest News
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)
InvestorsHub âĸ 2026-07-13T12:21:44Z
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street
The Fly âĸ 2026-06-25T13:34:06Z
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate
Simply Wall St. âĸ 2026-06-13T12:43:30Z
Why Is TNXP Stock Rising Today?
Stocktwits âĸ 2026-06-08T13:46:10Z
Tonix prices 615,025 shares at $16.26 in registered direct offering
TipRanks âĸ 2025-12-30T13:00:46Z
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News
Simply Wall St. âĸ 2025-11-12T10:26:57Z
Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data
Insider Monkey âĸ 2025-10-29T15:57:23Z
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?
Pharma Voice âĸ 2025-09-30T07:46:20Z
FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide
Investor's Business Daily âĸ 2025-08-18T17:07:10Z
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years
Benzinga âĸ 2025-08-18T15:45:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,640,000 | $7,765,000 | $4,741,000 | $0 |
| Cost Of Revenue | $6,640,000 | $7,765,000 | $4,741,000 | $0 |
| Total Revenue | $13,107,000 | $10,094,000 | $7,768,000 | $0 |
| Operating Revenue | $13,107,000 | $10,094,000 | $7,768,000 | $0 |
| Expenses | ||||
| Interest Expense | $89,000 | $1,234,000 | - | - |
| Total Expenses | $135,798,000 | $85,244,000 | $126,148,000 | $112,091,000 |
| Other Income Expense | $-5,387,000 | $-53,674,000 | $1,722,000 | $1,873,000 |
| Other Non Operating Income Expenses | $-3,295,000 | $-867,000 | $1,722,000 | $1,873,000 |
| Net Non Operating Interest Income Expense | $4,057,000 | $-1,212,000 | - | $1,873,000 |
| Interest Expense Non Operating | $89,000 | $1,234,000 | - | - |
| Operating Expense | $129,158,000 | $77,479,000 | $121,407,000 | $112,091,000 |
| Other Operating Expenses | $-3,012,000 | $-2,594,000 | - | - |
| General And Administrative Expense | - | - | $34,752,000 | $30,215,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Net Interest Income | $4,057,000 | $-1,212,000 | - | $1,873,000 |
| Interest Income | $4,146,000 | $22,000 | - | $1,873,000 |
| Normalized Income | $-121,929,000 | $-77,229,000 | $-116,658,000 | $-110,218,000 |
| Net Income From Continuing And Discontinued Operation | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Total Operating Income As Reported | $-125,703,000 | $-136,701,000 | $-118,380,000 | $-112,091,000 |
| Net Income Common Stockholders | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-116,877,000 |
| Net Income | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Net Income Including Noncontrolling Interests | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Net Income Continuous Operations | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Pretax Income | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Special Income Charges | $-2,092,000 | $-58,957,000 | $0 | - |
| Interest Income Non Operating | $4,146,000 | $22,000 | - | $1,873,000 |
| Operating Income | $-122,691,000 | $-75,150,000 | $-118,380,000 | $-112,091,000 |
| Gross Profit | $6,467,000 | $2,329,000 | $3,027,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-14.57 | $-176.60 | $-14720.25 | $-65400.00 |
| Basic EPS | $-14.57 | $-176.60 | $-14720.25 | $-65400.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-119,915,000 | $-72,574,000 | $-114,089,000 | $-110,838,000 |
| Total Unusual Items | $-2,092,000 | $-52,807,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $-2,092,000 | $-52,807,000 | $0 | - |
| Reconciled Depreciation | $1,925,000 | $3,421,000 | $4,291,000 | $1,253,000 |
| EBITDA (Bullshit earnings) | $-122,007,000 | $-125,381,000 | $-114,089,000 | $-110,838,000 |
| EBIT | $-123,932,000 | $-128,802,000 | $-118,380,000 | $-112,091,000 |
| Diluted Average Shares | $8,511,318 | $736,339 | $7,925 | $1,786 |
| Basic Average Shares | $8,511,318 | $736,339 | $7,925 | $1,786 |
| Diluted NI Availto Com Stockholders | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-116,877,000 |
| Other Special Charges | $2,092,000 | - | - | - |
| Write Off | $0 | $58,957,000 | $0 | - |
| Research And Development | $44,486,000 | $39,972,000 | $86,655,000 | $81,876,000 |
| Selling General And Administration | $87,684,000 | $40,101,000 | $34,752,000 | $30,215,000 |
| Gain On Sale Of Security | - | $6,150,000 | - | - |
| Other Gand A | - | - | $34,752,000 | $30,215,000 |
| Preferred Stock Dividends | - | - | - | $6,659,000 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $245,030,000 | $139,438,000 | $94,817,000 | $207,062,000 |
| Total Assets | $277,171,000 | $162,890,000 | $154,457,000 | $225,690,000 |
| Total Non Current Assets | $48,295,000 | $43,888,000 | $106,689,000 | $94,913,000 |
| Other Non Current Assets | $2,175,000 | $951,000 | $1,129,000 | $264,000 |
| Goodwill And Other Intangible Assets | $120,000 | $120,000 | $10,708,000 | $120,000 |
| Other Intangible Assets | $120,000 | $120,000 | $9,743,000 | $120,000 |
| Current Assets | $228,876,000 | $119,002,000 | $47,768,000 | $130,777,000 |
| Other Current Assets | $3,904,000 | $3,169,000 | $2,570,000 | $2,505,000 |
| Inventory | $7,013,000 | $8,408,000 | $14,147,000 | $0 |
| Receivables | $10,322,000 | $8,649,000 | $6,103,000 | $8,043,000 |
| Other Receivables | $3,485,000 | $4,221,000 | $4,590,000 | $8,043,000 |
| Taxes Receivable | $566,000 | $565,000 | - | - |
| Accrued Interest Receivable | $0 | $180,000 | $1,513,000 | $0 |
| Accounts Receivable | $6,271,000 | $3,683,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $207,637,000 | $98,776,000 | $24,948,000 | $120,229,000 |
| Cash And Cash Equivalents | $207,637,000 | $98,776,000 | $24,948,000 | $120,229,000 |
| Prepaid Assets | - | - | $1,656,000 | $1,275,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $1,309,000 | $8,119,000 | $9,813,000 | $760,000 |
| Long Term Debt And Capital Lease Obligation | $1,184,000 | $5,025,000 | $7,193,000 | $328,000 |
| Current Debt And Capital Lease Obligation | $125,000 | $3,094,000 | $2,620,000 | $432,000 |
| Long Term Debt | - | $4,667,000 | $6,561,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $32,021,000 | $23,332,000 | $48,932,000 | $18,508,000 |
| Total Non Current Liabilities Net Minority Interest | $1,184,000 | $5,025,000 | $30,048,000 | $328,000 |
| Current Liabilities | $30,837,000 | $18,307,000 | $18,884,000 | $18,180,000 |
| Other Current Liabilities | $5,120,000 | $697,000 | $1,398,000 | $659,000 |
| Current Deferred Liabilities | $3,425,000 | $1,816,000 | $2,980,000 | $3,273,000 |
| Payables And Accrued Expenses | $16,023,000 | $8,204,000 | $7,525,000 | $10,171,000 |
| Payables | $8,114,000 | $4,546,000 | $3,782,000 | $8,068,000 |
| Accounts Payable | $8,114,000 | $4,546,000 | $3,782,000 | $8,068,000 |
| Derivative Product Liabilities | - | $0 | $22,855,000 | $0 |
| Equity | ||||
| Common Stock Equity | $245,150,000 | $139,558,000 | $105,525,000 | $207,182,000 |
| Total Equity Gross Minority Interest | $245,150,000 | $139,558,000 | $105,525,000 | $207,182,000 |
| Stockholders Equity | $245,150,000 | $139,558,000 | $105,525,000 | $207,182,000 |
| Gains Losses Not Affecting Retained Earnings | $-289,000 | $-255,000 | $-232,000 | $-167,000 |
| Other Equity Adjustments | $-289,000 | $-255,000 | $-232,000 | $-167,000 |
| Retained Earnings | $-854,715,000 | $-730,694,000 | $-600,658,000 | $-470,038,000 |
| Other | ||||
| Ordinary Shares Number | $12,788,069 | $4,385,929 | $18,317 | $3,823 |
| Share Issued | $12,788,069 | $4,385,929 | $18,317 | $3,823 |
| Tangible Book Value | $245,030,000 | $139,438,000 | $94,817,000 | $207,062,000 |
| Invested Capital | $245,150,000 | $144,225,000 | $112,086,000 | $207,182,000 |
| Working Capital | $198,039,000 | $100,695,000 | $28,884,000 | $112,597,000 |
| Capital Lease Obligations | $1,309,000 | $632,000 | $902,000 | $760,000 |
| Total Capitalization | $245,150,000 | $144,225,000 | $112,086,000 | $207,182,000 |
| Additional Paid In Capital | $1,100,141,000 | $870,503,000 | $706,415,000 | $677,375,000 |
| Capital Stock | $13,000 | $4,000 | $0 | $12,000 |
| Common Stock | $13,000 | $4,000 | $0 | $12,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,184,000 | $358,000 | $632,000 | $328,000 |
| Current Deferred Revenue | $3,425,000 | $1,816,000 | $2,980,000 | $3,273,000 |
| Current Capital Lease Obligation | $125,000 | $274,000 | $270,000 | $432,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,144,000 | $4,496,000 | $4,361,000 | $3,645,000 |
| Current Accrued Expenses | $7,909,000 | $3,658,000 | $3,743,000 | $2,103,000 |
| Net PPE | $46,000,000 | $42,817,000 | $94,852,000 | $94,529,000 |
| Accumulated Depreciation | $-6,022,000 | $-4,097,000 | $-5,362,000 | $-1,653,000 |
| Gross PPE | $52,022,000 | $46,914,000 | $100,214,000 | $96,182,000 |
| Leases | $203,000 | $34,000 | $34,000 | $34,000 |
| Other Properties | $16,393,000 | $12,689,000 | $22,728,000 | $19,155,000 |
| Machinery Furniture Equipment | $2,014,000 | $1,371,000 | $2,366,000 | $1,893,000 |
| Buildings And Improvements | $25,096,000 | $24,504,000 | $66,749,000 | $65,644,000 |
| Land And Improvements | $8,316,000 | $8,316,000 | $8,337,000 | $8,090,000 |
| Other Inventories | $1,000,000 | - | $508,000 | - |
| Finished Goods | $2,137,000 | $5,124,000 | $7,489,000 | $0 |
| Work In Process | $1,370,000 | $213,000 | $2,539,000 | $0 |
| Raw Materials | $2,506,000 | $3,071,000 | $3,611,000 | $0 |
| Goodwill | - | $0 | $965,000 | $0 |
| Construction In Progress | - | - | $0 | $1,366,000 |
| Inventories Adjustments Allowances | - | - | $-21,000 | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-103,213,000 | $-61,045,000 | $-109,898,000 | $-146,200,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-99,844,000 | $-60,925,000 | $-102,003,000 | $-98,053,000 |
| Cash Flow From Continuing Operating Activities | $-99,844,000 | $-60,925,000 | $-102,003,000 | $-98,053,000 |
| Operating Gains Losses | $2,092,000 | $-6,150,000 | $221,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-3,369,000 | $-120,000 | $-7,895,000 | $-48,147,000 |
| Investing Cash Flow | $-4,528,000 | $-120,000 | $-29,070,000 | $-48,147,000 |
| Cash Flow From Continuing Investing Activities | $-4,528,000 | $-120,000 | $-29,070,000 | $-48,147,000 |
| Net Other Investing Changes | $-1,159,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-13,760,000 | $0 | $-13,965,000 | $-47,250,000 |
| Issuance Of Capital Stock | $237,940,000 | $140,195,000 | $18,939,000 | $135,054,000 |
| Financing Cash Flow | $214,530,000 | $134,872,000 | $36,517,000 | $87,844,000 |
| Cash Flow From Continuing Financing Activities | $214,530,000 | $134,872,000 | $36,517,000 | $87,844,000 |
| Net Common Stock Issuance | $224,180,000 | $140,195,000 | $4,974,000 | $94,463,000 |
| Common Stock Issuance | $237,940,000 | $140,195,000 | $18,939,000 | $94,463,000 |
| Net Other Financing Charges | - | $-3,000,000 | $22,572,000 | - |
| Net Preferred Stock Issuance | - | $0 | $0 | $-6,659,000 |
| Preferred Stock Issuance | - | - | $0 | $40,591,000 |
| Other | ||||
| Repayment Of Debt | $-9,650,000 | $-2,350,000 | $0 | - |
| Interest Paid Supplemental Data | $89,000 | $1,234,000 | $88,000 | - |
| End Cash Position | $209,807,000 | $99,680,000 | $25,849,000 | $120,470,000 |
| Beginning Cash Position | $99,680,000 | $25,849,000 | $120,470,000 | $178,900,000 |
| Effect Of Exchange Rate Changes | $-31,000 | $4,000 | $-65,000 | $-74,000 |
| Changes In Cash | $110,158,000 | $73,827,000 | $-94,556,000 | $-58,356,000 |
| Proceeds From Stock Option Exercised | $0 | $27,000 | $29,000 | $40,000 |
| Common Stock Payments | $-13,760,000 | $0 | $-13,965,000 | $0 |
| Net Issuance Payments Of Debt | $-9,650,000 | $-2,350,000 | $8,942,000 | $0 |
| Net Long Term Debt Issuance | $-9,650,000 | $-2,350,000 | $8,942,000 | $0 |
| Long Term Debt Payments | $-9,650,000 | $-2,350,000 | $0 | - |
| Net PPE Purchase And Sale | $-3,369,000 | $-120,000 | $-6,896,000 | $-48,147,000 |
| Purchase Of PPE | $-3,369,000 | $-120,000 | $-7,895,000 | $-48,147,000 |
| Change In Working Capital | $8,545,000 | $5,775,000 | $-35,000 | $-2,000 |
| Change In Other Current Liabilities | $-303,000 | $-13,000 | $35,000 | $2,000 |
| Change In Payables And Accrued Expense | $12,902,000 | $2,117,000 | $-1,704,000 | $160,000 |
| Change In Accrued Expense | $9,908,000 | $1,190,000 | $1,786,000 | $1,205,000 |
| Change In Payable | $2,994,000 | $927,000 | $-3,490,000 | $-1,045,000 |
| Change In Account Payable | $2,994,000 | $927,000 | $-3,490,000 | $-1,045,000 |
| Change In Prepaid Assets | $-3,161,000 | $3,613,000 | $1,573,000 | $-164,000 |
| Change In Inventory | $1,726,000 | $3,741,000 | $61,000 | $0 |
| Change In Receivables | $-2,619,000 | $-3,683,000 | $0 | - |
| Changes In Account Receivables | $-2,619,000 | $-3,683,000 | $0 | - |
| Other Non Cash Items | $4,898,000 | $840,000 | $903,000 | - |
| Stock Based Compensation | $6,017,000 | $4,778,000 | $9,275,000 | $10,914,000 |
| Asset Impairment Charge | $700,000 | $60,447,000 | $0 | - |
| Depreciation Amortization Depletion | $1,925,000 | $3,421,000 | $4,291,000 | $1,253,000 |
| Depreciation And Amortization | $1,925,000 | $3,421,000 | $4,291,000 | $1,253,000 |
| Net Income From Continuing Operations | $-124,021,000 | $-130,036,000 | $-116,658,000 | $-110,218,000 |
| Issuance Of Debt | - | $0 | $8,942,000 | $0 |
| Preferred Stock Payments | - | $0 | $0 | $-47,250,000 |
| Long Term Debt Issuance | - | $0 | $8,942,000 | $0 |
| Net Business Purchase And Sale | - | $0 | $-22,174,000 | $0 |
| Purchase Of Business | - | $0 | $-22,174,000 | $0 |
| Sale Of PPE | - | $0 | $999,000 | $0 |
| Gain Loss On Investment Securities | - | $-6,150,000 | $283,000 | - |
| Gain Loss On Sale Of PPE | - | $0 | $-62,000 | $0 |
| Change In Other Working Capital | - | - | - | $2,000 |
Fetched: 2026-07-15